CO2021017504A2 - Derivados de benzisoxazol sulfonamida - Google Patents

Derivados de benzisoxazol sulfonamida

Info

Publication number
CO2021017504A2
CO2021017504A2 CONC2021/0017504A CO2021017504A CO2021017504A2 CO 2021017504 A2 CO2021017504 A2 CO 2021017504A2 CO 2021017504 A CO2021017504 A CO 2021017504A CO 2021017504 A2 CO2021017504 A2 CO 2021017504A2
Authority
CO
Colombia
Prior art keywords
compounds
sulfonamide derivatives
patients
cell growth
abnormal cell
Prior art date
Application number
CONC2021/0017504A
Other languages
English (en)
Inventor
Robert Louis Hoffman
Ylva Elisabet Bergman Bozikis
Oleg Brodsky
Michelle Ang Camerino
Samantha Elizabeth Greasley
Robert Arnold Kumpf
Pei-Pei Kung
Paul Francis Richardson
Paul Anthony Stupple
Scott Channing Sutton
Original Assignee
Pfizer
Ctxt Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Ctxt Pty Ltd filed Critical Pfizer
Publication of CO2021017504A2 publication Critical patent/CO2021017504A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con los compuestos de la fórmula (I) o sales farmacéuticamente aceptables de los mismos, en donde el Anillo A, R1-R8, y n se definen en la presente. Los derivados de benzisoxazol sulfonamida novedosos son útiles para el tratamiento de crecimiento celular anormal, tal como cáncer, en pacientes. Las modalidades adicionales relacionadas con las composiciones farmacéuticas que contienen los compuestos y a métodos de utilización los compuestos y composiciones en el tratamiento de crecimiento celular anormal en pacientes.
CONC2021/0017504A 2019-06-18 2021-12-21 Derivados de benzisoxazol sulfonamida CO2021017504A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962863199P 2019-06-18 2019-06-18
US201962953223P 2019-12-24 2019-12-24
US202063025278P 2020-05-15 2020-05-15
PCT/IB2020/055589 WO2020254946A1 (en) 2019-06-18 2020-06-16 Benzisoxazole sulfonamide derivatives

Publications (1)

Publication Number Publication Date
CO2021017504A2 true CO2021017504A2 (es) 2022-01-17

Family

ID=71738189

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0017504A CO2021017504A2 (es) 2019-06-18 2021-12-21 Derivados de benzisoxazol sulfonamida

Country Status (29)

Country Link
US (2) US11492346B2 (es)
EP (2) EP3986890B1 (es)
JP (2) JP7352662B2 (es)
KR (1) KR20220024671A (es)
CN (1) CN114364672A (es)
AU (2) AU2020296361A1 (es)
BR (1) BR112021025528A2 (es)
CA (1) CA3143666C (es)
CL (1) CL2021003372A1 (es)
CO (1) CO2021017504A2 (es)
CR (1) CR20210627A (es)
DK (1) DK3986890T3 (es)
EC (1) ECSP21091615A (es)
ES (1) ES2969616T3 (es)
FI (1) FI3986890T3 (es)
HR (1) HRP20231501T1 (es)
HU (1) HUE064683T2 (es)
IL (1) IL288802A (es)
LT (1) LT3986890T (es)
MD (1) MD3986890T2 (es)
MX (1) MX2021016085A (es)
PE (1) PE20220808A1 (es)
PL (1) PL3986890T3 (es)
PT (1) PT3986890T (es)
RS (1) RS64931B1 (es)
SI (1) SI3986890T1 (es)
TW (1) TWI787620B (es)
UY (1) UY38752A (es)
WO (1) WO2020254946A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201810092D0 (en) * 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CN114502540A (zh) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 Tead抑制剂和其用途
WO2020254946A1 (en) * 2019-06-18 2020-12-24 Pfizer Inc. Benzisoxazole sulfonamide derivatives
WO2022013369A1 (en) * 2020-07-15 2022-01-20 Pfizer Inc. Kat6 inhibitor methods and combinations for cancer treatment
WO2022187688A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent kras-binding compounds for therapeutic purposes
WO2022187693A1 (en) * 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
CA3221048A1 (en) * 2021-05-21 2022-11-24 Aurigene Oncology Limited Fused isoxazolyl compounds as kat6a inhibitors
WO2023280182A1 (zh) * 2021-07-05 2023-01-12 杭州英创医药科技有限公司 作为kat6抑制剂的化合物
KR20240046530A (ko) 2021-08-10 2024-04-09 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도
CA3237830A1 (en) * 2021-11-16 2023-05-25 Insilico Medicine Ip Limited Lysine acetyltransferase 6a (kat6a) inhibitors and uses thereof
WO2023114710A1 (en) * 2021-12-13 2023-06-22 Aurigene Oncology Limited Fused benzoisoxazolyl compounds as kat6a inhibitors
WO2023192817A1 (en) 2022-03-28 2023-10-05 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230416240A1 (en) * 2022-06-16 2023-12-28 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2358031A (en) 1944-09-12 Substituted thiadiazoles
US3064003A (en) 1962-11-13 Carboxylic acid derivatives of sub-
US2525321A (en) 1949-01-07 1950-10-10 American Cyanamid Co Hydroxybenzenesulfonamidoisoxazoles and preparation of same
GB689281A (en) 1950-02-18 1953-03-25 Lunbeck Corp Improvements in or relating to the production of sulphanilamido-thiadiazoles
DE1102745B (de) 1959-06-06 1961-03-23 Boehringer & Soehne Gmbh Verfahren zur Herstellung von 5-Sulfanilamidoisoxazolen
BE617370A (fr) 1961-05-09 1962-11-08 Ciba Geigy Procédé de préparation du 2,5-di-[benzoxazolyl-(2')]-thiofène
US3332942A (en) 1962-11-02 1967-07-25 White Lab Inc Substituted thiadiazoles
JPS498255B1 (es) 1970-10-08 1974-02-25
US3960854A (en) 1972-03-20 1976-06-01 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
US3951967A (en) 1972-03-20 1976-04-20 Merck & Co., Inc. 7-Mercapto(or thio)-benzothiadiazine products
DE2617809C2 (de) 1976-04-23 1984-09-20 Basf Ag, 6700 Ludwigshafen Verfahren zur Stabilisierung von Chromdioxid-Magnetpigmenten und seine Verwendung
JPS6042794B2 (ja) 1977-09-27 1985-09-25 三共株式会社 イソオキサゾリウム塩，およびその製造方法
US4251664A (en) 1978-05-24 1981-02-17 Henkel Corporation Sulfonamidothiadiazoles, metal complexes thereof, and solutions containing such compounds for use in extraction of metal values
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS603685B2 (ja) 1980-04-15 1985-01-30 日本コロムビア株式会社 絵入りレコ−ド盤の製造方法
GB8427618D0 (en) 1984-11-01 1984-12-05 Shell Int Research Anticoccidial compositions
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
JPS63238006A (ja) 1987-03-26 1988-10-04 Shionogi & Co Ltd イモチ防除剤
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
FI93954C (fi) 1988-11-29 1995-06-26 Warner Lambert Co Menetelmä lääkeaineina käyttökelpoisten 3,5-di-tert-butyyli-4-hydroksifenyylisubstituoitujen 1,2,4- ja 1,3,4-tiadiatsolien sekä oksadiatsolien ja triatsolien valmistamiseksi
JPH03258771A (ja) 1990-03-09 1991-11-19 Tosoh Corp スルホンアミド誘導体、その製法及びそれを有効成分として含有する除草剤
TW224462B (es) 1992-02-24 1994-06-01 Squibb & Sons Inc
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
EP0626174A3 (en) 1993-04-21 1996-01-03 Takeda Chemical Industries Ltd Method and composition for the prophylaxis and / or treatment of underactive organs.
JP3901229B2 (ja) 1994-05-13 2007-04-04 Ｎｔｎ株式会社 耐熱・潤滑性樹脂組成物
EA199900808A1 (ru) 1995-04-04 2000-06-26 Тексаз Байотекнолоджи Корпорейшн Бифенилсульфонамиды и их производные, модулирующие активность эндотелина
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
WO1998021186A1 (en) 1996-11-13 1998-05-22 Cephalon, Inc. Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors
PL197843B1 (pl) 1997-04-28 2008-05-30 Encysive Pharmaceuticals Inc Farmaceutycznie dopuszczalne sole metali alkalicznych ze związkami sulfonoamidowymi, środek farmaceutyczny, zastosowanie farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi, sposób wytwarzania liofilizowanego proszku i sposób wytwarzania farmaceutycznie dopuszczalnych soli metali alkalicznych ze związkami sulfonoamidowymi
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
TR200201413T2 (tr) 1999-09-17 2003-02-21 Millennium Pharmaceuticals, Inc. Faktör Xa' nın inhibitörleri.
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
GB0127344D0 (en) 2001-11-14 2002-01-02 Cancer Res Ventures Ltd Assay method
IL160630A0 (en) 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003292485A (ja) 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
BRPI0412876A (pt) 2003-07-22 2006-10-03 Janssen Pharmaceutica Nv derivados de quinolinona como inibidores de c-fms quinase
EP1673357A2 (en) 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
EP1812426B1 (en) 2004-10-12 2011-06-08 Decode Genetics, Ehf Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
CN101218226A (zh) 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
WO2007039174A2 (en) 2005-10-06 2007-04-12 Sanofi-Aventis Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation and their use as pharmaceuticals
KR20080050468A (ko) 2005-10-06 2008-06-05 사노피-아벤티스 Ｎ-[1,3,4]-티아디아졸-2-일-벤젠 설폰아미드, 이의 제조방법 및 약제로서의 이의 용도
DE102005055355A1 (de) 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
NZ569694A (en) 2005-12-21 2011-06-30 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
WO2008022286A2 (en) 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CA2670026A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterotricyclic metalloprotease inhibitors
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
EP2173743A2 (en) 2007-07-13 2010-04-14 Icagen, Inc. Sodium channel inhibitors
CA2704336A1 (en) 2007-11-01 2009-05-07 Sirtris Pharmaceuticals, Inc. Amide derivatives as sirtuin modulators
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
ATE549332T1 (de) 2007-12-26 2012-03-15 Sanofi Sa Zyklische pyridyl-n-(1,3,4)-thiadiazol-2-yl- benzol-sulfonamide, verfahren für ihre herstellung und anwendung als pharmaka
WO2010019788A1 (en) 2008-08-13 2010-02-18 Smed-Ta/Td. Llc Drug delivery implants
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
CN101845043A (zh) 2010-01-15 2010-09-29 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
CN101747325A (zh) 2010-01-15 2010-06-23 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
WO2011085575A1 (zh) 2010-01-15 2011-07-21 江苏省农药研究所股份有限公司 邻杂环甲酰苯胺类化合物及其合成方法和应用
AU2011245441B2 (en) 2010-04-29 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
PL220630B1 (pl) 2012-12-28 2015-11-30 Inst Immunologii I Terapii Doświadczalnej Pan Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
WO2015112465A1 (en) 2014-01-24 2015-07-30 Merck Sharp & Dohme Corp. Isoquinoline derivatives as mgat2 inhibitors
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN107098846B (zh) * 2016-02-26 2020-10-09 中国医学科学院药物研究所 N-酰基磺酰胺类FBPase抑制剂、其制备方法、药物组合物及用途
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
WO2018102419A1 (en) 2016-11-29 2018-06-07 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
WO2020254946A1 (en) 2019-06-18 2020-12-24 Pfizer Inc. Benzisoxazole sulfonamide derivatives

Also Published As

Publication number Publication date
US20230174522A1 (en) 2023-06-08
KR20220024671A (ko) 2022-03-03
JP2023175821A (ja) 2023-12-12
EP3986890A1 (en) 2022-04-27
CL2021003372A1 (es) 2022-10-07
ECSP21091615A (es) 2022-01-31
PT3986890T (pt) 2024-01-17
CA3143666A1 (en) 2020-12-24
EP4299135A2 (en) 2024-01-03
CN114364672A (zh) 2022-04-15
HUE064683T2 (hu) 2024-04-28
ES2969616T3 (es) 2024-05-21
UY38752A (es) 2021-01-29
HRP20231501T1 (hr) 2024-03-01
US11492346B2 (en) 2022-11-08
TW202115048A (zh) 2021-04-16
PL3986890T3 (pl) 2024-03-11
CA3143666C (en) 2024-06-11
EP3986890B1 (en) 2023-11-15
CR20210627A (es) 2022-02-08
AU2020296361A1 (en) 2022-01-06
SI3986890T1 (sl) 2024-03-29
EP4299135A3 (en) 2024-02-28
LT3986890T (lt) 2023-12-11
US20200399258A1 (en) 2020-12-24
RS64931B1 (sr) 2023-12-29
DK3986890T3 (da) 2023-12-18
IL288802A (en) 2022-02-01
JP2022537285A (ja) 2022-08-25
TWI787620B (zh) 2022-12-21
PE20220808A1 (es) 2022-05-20
MX2021016085A (es) 2022-04-20
FI3986890T3 (fi) 2024-01-15
BR112021025528A2 (pt) 2022-04-19
AU2023274178A1 (en) 2024-02-15
MD3986890T2 (ro) 2024-04-30
WO2020254946A1 (en) 2020-12-24
JP7352662B2 (ja) 2023-09-28

Similar Documents

Publication Publication Date Title
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
UY38553A (es) Inhibidores de cdk2
DOP2020000191A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
UY37900A (es) Nuevos derivados de rapamicina
BR112021017620A2 (pt) Compostos macrocíclicos
CO2022015448A2 (es) Compuestos de azalactama como inhibidores de hpk1
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CL2022000956A1 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2023017970A2 (es) Inhibidores de mutación de her2
CU20160157A7 (es) Derivados de diheterociclo enlazado a cicloalquilo
UY36074A (es) ?derivados de dihidropirrolopirimidina? .
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
CL2023001277A1 (es) Derivados de pirazol como inhibidores de la ret-cinasa
UY39303A (es) Inhibidores de mutación her2
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
AR122805A1 (es) Inhibidores de mutación her2